| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open … C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ... The lancet oncology 12 (8), 735-742, 2011 | 5036 | 2011 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 3253 | 2019 |
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open … YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ... The lancet oncology 15 (2), 213-222, 2014 | 2407 | 2014 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1833 | 2022 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1821 | 2015 |
| Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England Journal of Medicine 383 (18), 1711-1723, 2020 | 1633 | 2020 |
| Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled … K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ... The Lancet Oncology 17 (5), 577-589, 2016 | 1340 | 2016 |
| First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open … L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... The Lancet Oncology 22 (2), 198-211, 2021 | 1204 | 2021 |
| First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open … YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu, Y Cheng, B Han, ... Annals of oncology 26 (9), 1883-1889, 2015 | 821 | 2015 |
| Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial L Paz-Ares, EH Tan, K O’Byrne, L Zhang, V Hirsh, M Boyer, JCH Yang, ... Annals of Oncology 28 (2), 270-277, 2017 | 596 | 2017 |
| Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ... The lancet oncology 16 (8), 897-907, 2015 | 519 | 2015 |
| Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell … C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ... Annals of Oncology 26 (9), 1877-1883, 2015 | 500 | 2015 |
| The diversity of gut microbiome is associated with favorable responses to anti–programmed death 1 immunotherapy in Chinese patients with NSCLC Y Jin, H Dong, L Xia, Y Yang, Y Zhu, Y Shen, H Zheng, C Yao, Y Wang, ... Journal of Thoracic Oncology 14 (8), 1378-1389, 2019 | 468 | 2019 |
| BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with … C Zhou, YL Wu, G Chen, X Liu, Y Zhu, S Lu, J Feng, J He, B Han, J Wang, ... Journal of clinical oncology 33 (19), 2197-2204, 2015 | 449 | 2015 |
| Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial YL Wu, S Lu, Y Cheng, C Zhou, J Wang, T Mok, L Zhang, HY Tu, L Wu, ... Journal of Thoracic Oncology 14 (5), 867-875, 2019 | 367 | 2019 |
| Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC M Tsuboi, RS Herbst, T John, T Kato, M Majem, C Grohé, J Wang, ... New England Journal of Medicine 389 (2), 137-147, 2023 | 362 | 2023 |
| IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ... Journal of Thoracic Oncology 15 (5), 709-740, 2020 | 347 | 2020 |
| Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non–small-cell lung cancer: a phase 3 randomized clinical trial J Wang, S Lu, X Yu, Y Hu, Y Sun, Z Wang, J Zhao, Y Yu, C Hu, K Yang, ... JAMA oncology 7 (5), 709-717, 2021 | 325 | 2021 |
| Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer YL Wu, JCH Yang, DW Kim, S Lu, J Zhou, T Seto, JJ Yang, N Yamamoto, ... Journal of clinical oncology 36 (14), 1405-1411, 2018 | 323 | 2018 |
| Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind … L Zhang, S Ma, X Song, B Han, Y Cheng, C Huang, S Yang, X Liu, Y Liu, ... The lancet oncology 13 (5), 466-475, 2012 | 322 | 2012 |
